Thus, to the best of our knowledge, this is the first research to use pan-cancer analysis of TGR5 across various tumor types and investigate the comprehensive overview of its potential role as an onco-immunological biomarker in tumor staging and prognosis. Here, GPBAR1 is linked to cancer.